|
Phenotype
|
Fish
|
Conditions
|
Figures
|
|
whole organism cdkn1a expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
whole organism dead, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
trunk mdm2 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
trunk smc5 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk septin6 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk aaas expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk knl1 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk scrib expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
whole organism bcl2a expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
inner ear smc5 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
whole organism col11a2 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 6
from Ren et al., 2024
|
|
trunk cenpk expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
neutrophilic myelocyte mpeg1.2 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
otolith otomp expression decreased distribution, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
trunk mis18a expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk cep131 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
otolith stm expression decreased distribution, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
inner ear foxm1 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
otolith stm expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
trunk ccng2 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
common myeloid progenitor gata1a expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
whole organism pax2a expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 6
from Ren et al., 2024
|
|
inner ear apoptotic process increased occurrence, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
whole organism tp53 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
inner ear fanci expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
macula utricle cahz expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
otic vesicle decreased size, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 1 ,
Figure 3
from Ren et al., 2024
|
|
trunk eme1 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
neutrophilic myelocyte spi1b expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
trunk pard3ab expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
neutrophilic myelocyte cebpa expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
otolith otomp expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
whole organism casp8 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
trunk mdm4 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
inner ear slx4 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
otic vesicle protrusion absent, ameliorated
|
dhx38hzu20/hzu20
|
chemical treatment by environment: p53 inhibitor
|
Figure 3
from Ren et al., 2024
|
|
whole organism gadd45ba expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
whole organism ret expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 6
from Ren et al., 2024
|
|
inner ear rad9a expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
intrinsic apoptotic signaling pathway by p53 class mediator increased occurrence, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
trunk cdkn1a expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
intermediate cell mass of mesoderm gata1a expression amount, ameliorated
|
dhx38hzu20/hzu20
|
chemical treatment by environment: p53 inhibitor
|
Fig. 8
from Tu et al., 2022
|
|
otic vesicle protrusion absent, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 1 ,
Figure 3
from Ren et al., 2024
|
|
inner ear mRNA splicing, via endonucleolytic cleavage and ligation disrupted, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5 ,
Figure 6
from Ren et al., 2024
|
|
trunk rad9a expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
whole organism viability, ameliorated
|
dhx38hzu20/hzu20
|
chemical treatment by environment: p53 inhibitor
|
Fig. 8
from Tu et al., 2022
|
|
trunk tonsl expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk recql expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
semicircular canal ncs1a expression absent, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
inner ear ints7 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
trunk eme1 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk trip12 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
common myeloid progenitor lmo2 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
whole organism baxa expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
erythroblast hbae1.1 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
semicircular canal dacha expression absent, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
inner ear development disrupted, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 1 ,
Figure 2
from Ren et al., 2024
|
|
trunk rad9a expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
whole organism bbc3 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
inner ear eme1 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
trunk aaas expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
intermediate cell mass of mesoderm myb expression amount, ameliorated
|
dhx38hzu20/hzu20
|
chemical treatment by environment: p53 inhibitor
|
Fig. 8
from Tu et al., 2022
|
|
trunk double-strand break repair decreased process quality, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
granulocyte decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 2
from Tu et al., 2022
|
|
trunk cell cycle process decreased process quality, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk dtl expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk chromosome segregation decreased process quality, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk trip12 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
whole organism cep290 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 6
from Ren et al., 2024
|
|
neutrophilic myelocyte mpx expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
trunk tonsl expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
whole organism smad5 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 6
from Ren et al., 2024
|
|
semicircular canal bmp4 expression absent, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
trunk kdm8 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk smc5 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk dtl expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk ccnb2 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk knl1 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk bbc3 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
trunk kdm8 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk septin6 expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk scrib expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk mak expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
whole organism masp1 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 6
from Ren et al., 2024
|
|
whole organism spns2 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 6
from Ren et al., 2024
|
|
inner ear apoptotic process increased occurrence, ameliorated
|
dhx38hzu20/hzu20
|
chemical treatment by environment: p53 inhibitor
|
Figure 3
from Ren et al., 2024
|
|
trunk ccnb2 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
intermediate cell mass of mesoderm myb expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
trunk cenpk expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
inner ear nuclear chromosome damaged, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 4
from Ren et al., 2024
|
|
trunk ccng2 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk lzts2a expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
intermediate cell mass of mesoderm gata1a expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
inner ear rad17 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
inner ear tonsl expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
blood island macrophage decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 2
from Tu et al., 2022
|
|
trunk ift20 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6
from Tu et al., 2022
|
|
inner ear foxj1b expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
trunk mak expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk recql expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk mis18a expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk lzts2a expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
trunk cep131 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
inner ear blm expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
neutrophilic myelocyte mfap4.1 expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 1
from Tu et al., 2022
|
|
saccule cahz expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 2
from Ren et al., 2024
|
|
trunk tp53 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
otolith decreased size, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 1
from Ren et al., 2024
|
|
otic vesicle size, ameliorated
|
dhx38hzu20/hzu20
|
chemical treatment by environment: p53 inhibitor
|
Figure 3
from Ren et al., 2024
|
|
whole organism mdm2 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 3
from Ren et al., 2024
|
|
trunk pard3ab expression spatial pattern, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 7
from Tu et al., 2022
|
|
trunk microtubule cytoskeleton organization decreased process quality, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 6 ,
Fig. 7
from Tu et al., 2022
|
|
inner ear mms22l expression decreased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Figure 5
from Ren et al., 2024
|
|
intermediate cell mass of mesoderm tp53 expression increased amount, abnormal
|
dhx38hzu20/hzu20
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
macrophage EGFP expression decreased amount, abnormal
|
dhx38hzu20/hzu20; ihb20Tg/ihb20Tg
|
standard conditions
|
Fig. 2
from Tu et al., 2022
|
|
neutrophilic myelocyte EGFP expression increased amount, abnormal
|
dhx38hzu20/hzu20; zf4117Tg/zf4117Tg
|
standard conditions
|
Fig. 2
from Tu et al., 2022
|
|
caudal hematopoietic tissue hematopoietic multipotent progenitor cell EGFP expression increased amount, abnormal
|
dhx38hzu20/hzu20; is5Tg/is5Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
hematopoietic multipotent progenitor cell mitotic spindle DsRed expression spatial pattern, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
caudal hematopoietic tissue EGFP expression decreased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|
|
common myeloid progenitor mitotic spindle DsRed expression spatial pattern, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
caudal hematopoietic tissue EGFP expression amount, ameliorated
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
chemical treatment by environment: p53 inhibitor
|
Fig. 8
from Tu et al., 2022
|
|
caudal hematopoietic tissue blood cell DsRed expression amount, ameliorated
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
chemical treatment by environment: p53 inhibitor
|
Fig. 8
from Tu et al., 2022
|
|
hematopoietic multipotent progenitor cell mitotic spindle Ab21-tuba labeling spatial pattern, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
hematopoietic multipotent progenitor cell regulation of cell cycle phase transition decreased process quality, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 4
from Tu et al., 2022
|
|
caudal hematopoietic tissue hematopoietic multipotent progenitor cell DsRed expression increased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
common myeloid progenitor EGFP expression increased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 2 ,
Fig. 4
from Tu et al., 2022
|
|
common myeloid progenitor mitotic chromosome condensation decreased process quality, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
hematopoietic multipotent progenitor cell mitotic spindle EGFP expression spatial pattern, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
common myeloid progenitor mitotic spindle Ab21-tuba labeling spatial pattern, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
common myeloid progenitor regulation of cell cycle phase transition decreased process quality, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 4
from Tu et al., 2022
|
|
caudal hematopoietic tissue hematopoietic multipotent progenitor cell EGFP expression increased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
common myeloid progenitor mitotic spindle EGFP expression spatial pattern, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
caudal hematopoietic tissue programmed cell death increased occurrence, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 4
from Tu et al., 2022
|
|
caudal hematopoietic tissue hematopoietic stem cell differentiation decreased occurrence, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
caudal hematopoietic tissue myeloid cell differentiation premature, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
caudal hematopoietic tissue hematopoietic stem cell differentiation premature, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
caudal hematopoietic tissue hematopoietic multipotent progenitor cell DsRed expression decreased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
caudal hematopoietic tissue hematopoietic multipotent progenitor cell EGFP expression decreased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 3
from Tu et al., 2022
|
|
hematopoietic multipotent progenitor cell mitotic chromosome condensation decreased process quality, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 5
from Tu et al., 2022
|
|
common myeloid progenitor DsRed expression increased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 2 ,
Fig. 4
from Tu et al., 2022
|
|
caudal hematopoietic tissue blood cell DsRed expression decreased amount, abnormal
|
dhx38hzu20/hzu20; sd2Tg/sd2Tg; zf169Tg/zf169Tg
|
standard conditions
|
Fig. 8
from Tu et al., 2022
|